FY2026 EPS Estimates for NVO Increased by Erste Group Bank

Novo Nordisk A/S (NYSE:NVO) – Research analysts at Erste Group Bank lifted their FY2026 earnings per share (EPS) estimates for Novo Nordisk A/S in a research note issued on Tuesday, May 12th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $3.23 per share for the year, up from their previous forecast of $3.22. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.47 per share.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.

Other research analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Trading Down 0.9%

NVO opened at $44.32 on Tuesday. The firm has a market cap of $197.88 billion, a price-to-earnings ratio of 10.40, a price-to-earnings-growth ratio of 3.98 and a beta of 0.77. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The business’s 50 day moving average is $39.84 and its two-hundred day moving average is $46.59. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $25,000. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $25,000. Scarborough Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $26,000. WealthCollab LLC grew its stake in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the last quarter. Finally, American National Bank & Trust purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $28,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.